Suven's first clinical compound passes Phase I
This article was originally published in Scrip
Suven Life Sciences of India has reported promising results from a Swiss Phase I study of its central nervous system (CNS) compound SUVN-502. This is the first of Suven's NCEs to enter clinic trials from its pipeline of six products.
You may also be interested in...
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.
Alembic says it is 'comfortably placed' in terms of inventories and is seeing improving API supplies from China. The only area of some concern is outbound logistics against a backdrop of flights being halted and population lock-downs.